Skip to main content
Navamedic logo

Navamedic — Investor Relations & Filings

Ticker · NAVA ISIN · NO0010205966 LEI · 529900LKVQOR2SRUJU71 OL Wholesale and retail trade
Open in API
Filings indexed 825 across all filing types
Latest filing 2020-02-13 Investor Presentation
Country NO Norway
Listing OL NAVA

About Navamedic

https://navamedic.com/

Navamedic is a pharmaceutical company that develops, produces, and commercializes a diverse portfolio of medicines and related health products. The company's offerings include specialty pharmaceuticals, branded generics, and consumer health items. Its product portfolio addresses various medical needs, with treatments for conditions such as obesity, Parkinson's disorder, and inborn errors of metabolism, in addition to antibiotics. Serving as a reliable supplier and distribution partner, Navamedic provides high-quality products to hospitals and pharmacies, with a strong presence in the Nordic region and the Netherlands. The company focuses on improving patient outcomes through innovations, including advancements in personalized treatment for Parkinson's care.

Recent filings

Filing Released Lang Actions
Navamedic ASA: Q4 2019 financial results
Investor Presentation Classification · 99% confidence The document is titled "Fourth quarter results 2019 Navamedic ASA" and contains detailed financial tables for Q4 2019 and the full year 2019, including Profit and Loss, Assets, and Cash Flow statements. It also discusses business performance, growth strategy, and outlook. This structure is characteristic of a comprehensive financial report covering a period shorter than a full year (quarterly results). Therefore, it aligns best with the Interim / Quarterly Report category (IR). It is not an Earnings Release (ER) because it is a detailed report with full financial statements, not just highlights. It is also not a 10-K as it is quarterly.
2020-02-13 Norwegian
Navamedic ASA: Q4 2019 financial results
Earnings Release Classification · 100% confidence The document explicitly states it contains the "Q4 2019 financial results" for Navamedic ASA, providing key figures like revenues (NOK 47.3 million) and EBITDA (negative NOK 8.0 million) for the quarter and full year. This content structure—reporting period results, CEO commentary, and financial metrics—is characteristic of an Earnings Release (ER). Although it mentions an attached quarterly presentation, the text itself is the primary announcement of the results, not just an announcement of the report's availability. Therefore, it fits the definition of an Earnings Release (ER). Q4 2019
2020-02-13 English
Navamedic ASA: Invitation to 2019 fourth quarter presentation
Report Publication Announcement Classification · 98% confidence The document is an invitation to a presentation of the 2019 fourth quarter figures, specifying the date, time, location, and webcast details. It is not the actual earnings release (ER) or the full interim report (IR), but rather an announcement about the upcoming event where those results will be discussed. Since it is an announcement regarding the publication/presentation of financial results, it fits best under Report Publication Announcement (RPA), which covers announcements about the timing or release of company reports.
2020-02-12 English
Navamedic ASA acquires marketing authorisations for antibiotics in the Nordics
Regulatory Filings Classification · 100% confidence The document announces that Navamedic ASA has entered into a term sheet to acquire marketing authorisations for antibiotics in the Nordics. This transaction involves the acquisition of assets (marketing authorisations) and is described as an 'important step in Navamedic’s growth strategy.' This type of corporate action, involving the acquisition or divestiture of business assets or significant strategic agreements that impact the capital structure or future operations, best fits the 'Capital/Financing Update' category, although it is specifically an M&A-related asset purchase. Given the options, 'TAR' (M&A Activity) is the most appropriate fit for an acquisition announcement, even if it's an asset purchase rather than a full company takeover. It is not an earnings release (ER), a general regulatory filing (RNS), or a report publication announcement (RPA) as it contains substantive news, not just a notice about a report.
2020-02-07 English
Navamedic ASA Expands Alflorex® distribution to the Netherlands and Denmark
Regulatory Filings Classification · 100% confidence The document is a short press release dated January 24, 2020, announcing a business development: Navamedic ASA expanding the distribution of its product Alflorex® into the Netherlands and referencing a recent launch in Denmark. It details strategic partnerships and product classification (medical Class IIb). This type of announcement, focusing on commercial agreements, market expansion, and product updates outside of mandatory financial reporting (like 10-K or ER), fits best under a general regulatory announcement or news release category. Since it is not a formal financial report (10-K, IR, ER), a management change (MANG), or a specific transaction (CAP, POS), the most appropriate classification is the general regulatory filing/announcement category, RNS, as it is a material, non-financial update released to the market.
2020-01-24 English
Navamedic ASA: Exercise of employee share options
Share Issue/Capital Change Classification · 98% confidence The document explicitly details the exercise of employee share options by three employees, resulting in the issuance of 275,000 new shares and an increase in the company's share capital. It also reports the new shareholdings of primary insiders (directors/executives) after the exercise. This activity directly relates to changes in the company's share structure due to employee compensation plans, which falls under 'Share Issue/Capital Change' (SHA) or potentially 'Transaction in Own Shares' (POS) if the shares were repurchased previously. Since the text focuses on the capital increase via new share issuance following option exercise, SHA is the most precise fit, as it covers capital structure changes resulting from share issuance. It is not a Director's Dealing (DIRS) as it reports option exercise/issuance, not open market trades by insiders, nor is it a general financing update (CAP).
2020-01-24 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.